Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines

On April 9, 2018 Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, reported upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) (AACR 2018), taking place April 14-18, 2018 in Chicago, IL (Press release, Genocea Biosciences, APR 9, 2018, View Source [SID1234525216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster 15: "Neoantigen identification using the ATLAS T cell profiling platform highlights the need to empirically define neoantigens"
Vaccines Session 1, Immunology Track
Sunday, April 15, 2018 from 1 pm to 5 pm CDT
Link to abstract

Poster 5718: "Ex vivo ATLAS-identification of neoantigens for personalized cancer immunotherapy in mouse melanoma"
Neoantigens in Cancer Session, Immunology Track
Wednesday, April 18, 2018 from 8 am to 12 pm CDT